R&G PharmaStudies Valuation

Is 301333 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Share Price vs Fair Value

What is the Fair Price of 301333 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow

Simply Wall St

CN¥21.71

Fair Value

120.3% overvalued

Number of Analysts

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301333?

Key metric:

The above table shows the Price to Earnings ratio for 301333. This is calculated by dividing 301333's market cap by their current earnings.
What is 301333's PE Ratio?
PE Ratio	38.1x
Earnings	CN¥121.09m
Market Cap	CN¥4.55b

301333 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.8x
Enterprise Value/EBITDA	29.3x
PEG Ratio	1.8x

Price to Earnings Ratio vs Peers

How does 301333's PE Ratio compare to its peers?

The above table shows the PE ratio for 301333 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	48.3x
688222 HitGen	94.6x	20.3%	CN¥4.8b
688315 Novogene	26.4x	19.4%	CN¥4.8b
688710 Shanghai Innostar Biotechnology	32.7x	n/a	CN¥4.7b
688046 GemPharmatech	39.5x	24.2%	CN¥5.7b
301333 R&G PharmaStudies	38.1x	21.5%	CN¥4.5b

Price to Earnings Ratio vs Industry

How does 301333's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price to Earnings Ratio vs Fair Ratio

What is 301333's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301333 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	38.1x
Fair PE Ratio	24.5x

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target

Consensus Narrative from 2 Analysts

CN¥59.50

Fair Value

19.6% undervalued

Number of Analysts

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/24 11:09
End of Day Share Price	2025/01/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

R&G PharmaStudies Co., Ltd. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jin Zhang	China International Capital Corporation Limited
Shitong Han	Citic Securities Co., Ltd.
Yuan Yuan Sun	Industrial Securities Co. Ltd.